Acura Pharmaceuticals Net Income
| ACUR Stock | USD 0.0005 0.00 0.00% |
As of the 9th of February, Acura Pharmaceuticals shows the Standard Deviation of 25.59, mean deviation of 9.18, and Risk Adjusted Performance of 0.0824. Acura Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for twelve technical drivers for Acura Pharmaceuticals, which can be compared to its peers. Please confirm Acura Pharmaceuticals market risk adjusted performance, total risk alpha, as well as the relationship between the Total Risk Alpha and kurtosis to decide if Acura Pharmaceuticals is priced correctly, providing market reflects its regular price of 5.0E-4 per share. As Acura Pharmaceuticals appears to be a penny stock we also recommend to validate its jensen alpha numbers.
Acura Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acura Pharmaceuticals' valuation are provided below:Acura Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Acura |
Acura Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acura Pharmaceuticals' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acura Pharmaceuticals.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Acura Pharmaceuticals on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Acura Pharmaceuticals or generate 0.0% return on investment in Acura Pharmaceuticals over 90 days. Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercializ... More
Acura Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acura Pharmaceuticals' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acura Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0868 | |||
| Maximum Drawdown | 150.0 | |||
| Value At Risk | (20.00) |
Acura Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acura Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acura Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Acura Pharmaceuticals historical prices to predict the future Acura Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0824 | |||
| Jensen Alpha | 2.35 | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (3.75) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acura Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acura Pharmaceuticals February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0824 | |||
| Market Risk Adjusted Performance | (3.74) | |||
| Mean Deviation | 9.18 | |||
| Coefficient Of Variation | 1107.36 | |||
| Standard Deviation | 25.59 | |||
| Variance | 654.68 | |||
| Information Ratio | 0.0868 | |||
| Jensen Alpha | 2.35 | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (3.75) | |||
| Maximum Drawdown | 150.0 | |||
| Value At Risk | (20.00) | |||
| Skewness | 3.77 | |||
| Kurtosis | 20.31 |
Acura Pharmaceuticals Backtested Returns
Acura Pharmaceuticals is out of control given 3 months investment horizon. Acura Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0973, which signifies that the company had a 0.0973 % return per unit of risk over the last 3 months. We are able to break down and analyze data for seventeen different technical indicators, which can help you to evaluate if expected returns of 2.38% are justified by taking the suggested risk. Use Acura Pharmaceuticals Standard Deviation of 25.59, mean deviation of 9.18, and Risk Adjusted Performance of 0.0824 to evaluate company specific risk that cannot be diversified away. Acura Pharmaceuticals holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.61, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Acura Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Acura Pharmaceuticals is likely to outperform the market. Use Acura Pharmaceuticals jensen alpha and rate of daily change , to analyze future returns on Acura Pharmaceuticals.
Auto-correlation | 0.00 |
No correlation between past and present
Acura Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between Acura Pharmaceuticals time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acura Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current Acura Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Acura Pharmaceuticals reported net income of (1.21 Million). This is 100.35% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.21% higher than that of the company.
Acura Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acura Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Acura Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acura Pharmaceuticals by comparing valuation metrics of similar companies.Acura Pharmaceuticals is currently under evaluation in net income category among its peers.
Acura Fundamentals
| Return On Asset | -0.38 | |||
| Profit Margin | (0.51) % | |||
| Operating Margin | (0.49) % | |||
| Current Valuation | 3.49 M | |||
| Shares Outstanding | 65.09 M | |||
| Shares Owned By Insiders | 19.27 % | |||
| Shares Owned By Institutions | 3.00 % | |||
| Number Of Shares Shorted | 89.85 K | |||
| Price To Earning | 125.00 X | |||
| Price To Book | 24.11 X | |||
| Price To Sales | 1.45 X | |||
| Revenue | 3.57 M | |||
| Gross Profit | 1.79 M | |||
| EBITDA | (633 K) | |||
| Net Income | (1.21 M) | |||
| Cash And Equivalents | 89 K | |||
| Total Debt | 105 K | |||
| Debt To Equity | 2.40 % | |||
| Current Ratio | 0.86 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (719 K) | |||
| Short Ratio | 0.73 X | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 12 | |||
| Beta | 2.45 | |||
| Market Capitalization | 3.25 M | |||
| Total Asset | 1.74 M | |||
| Retained Earnings | (418.63 M) | |||
| Working Capital | 10.89 M | |||
| Current Asset | 14.13 M | |||
| Current Liabilities | 3.24 M | |||
| Net Asset | 1.74 M |
About Acura Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acura Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acura Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acura Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acura Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acura OTC Stock
The ability to find closely correlated positions to Acura Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharmaceuticals to buy it.
The correlation of Acura Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Acura OTC Stock Analysis
When running Acura Pharmaceuticals' price analysis, check to measure Acura Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharmaceuticals is operating at the current time. Most of Acura Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acura Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acura Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acura Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.